Cybin Inc company information, Employees & Contact Information

Cybin Announces $175 Million Registered Direct Offering Business Wire

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder Investing News Network

Cybin to Participate in the Cantor Global Healthcare Conference 2025 Yahoo Finance

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Business Wire

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results Yahoo Finance

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 Business Wire

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights Yahoo Finance

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference Yahoo Finance

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures Yahoo Finance

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics Yahoo Finance

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder Business Wire

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder Business Wire

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights Yahoo Finance

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs Business Wire

Cybin Inc. Securities Lawsuit Investigation Claim Depot

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder Yahoo Finance

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results Business Wire

Synthesis and Structure–Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist ACS Publications

Cybin Announces Completion of Previously Announced Share Consolidation Business Wire

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics Business Wire

Cybin Announces up to US$64 Million Offering of Units Business Wire

Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose Business Wire

Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds Business Wire

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder Business Wire

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses Business Wire

Cybin to Acquire Small Pharma Inc. USA Today

Cybin Announces Completion of Previously Announced Share Consolidation Stock Titan

Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference Investing News Network

Cybin Reports Third Quarter Financial Results and Recent Business Highlights Stock Titan

Cybin's EMBARK Program Announces Graduation of Facilitators Investing News Network

Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds Investing News Network

Cybin Acquires DMT Clinical Study from Entheon Biomedical Business Wire

Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting Investing News Network

Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder Investing News Network

Cybin Announces Final Adelia Milestone Achievement Investing News Network

CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth Psychedelic Alpha

Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain Business Wire

Cybin Expands to Europe and Provides Update on Intellectual Property Portfolio Business Wire

Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder Business Wire

Cybin Announces Conditional Listing Approval from NYSE American Business Wire

Cybin Corp Announces Doug Drysdale as Chief Executive Officer Business Wire

Cybin Goes Public on NEO Exchange Business Wire

Cybin Corp Announces Partnership with the Toronto Centre for Psychedelic Science Business Wire

Cybin Completes Reverse Take-Over Transaction Business Wire

CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program FinancialContent

Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference | User | kanerepublican.com FinancialContent

User FinancialContent

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference By Investing.com Investing.com South Africa

Cybin Achieves Research and Development Milestones Ahead of Projected Timelines | User | kanerepublican.com FinancialContent

Cybin & The Chopra Foundation Recognize World Mental Health Day | User | kanerepublican.com FinancialContent

Cybin Inc. Reports First Quarter Financial Results and Recent Business Highlights | News | postregister.com FinancialContent